- Home
- CZNC vs BNTC Comparison
CZNC vs BNTC Comparison
Compare CZNC & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | BNTC |
|---|---|---|
| Founded | 1864 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.0M | 411.4M |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CZNC | BNTC |
|---|---|---|
| Price | $20.89 | $11.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $23.50 | ★ $27.67 |
| AVG Volume (30 Days) | 26.1K | ★ 96.3K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | 7.64 | ★ 80.94 |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1,052.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.02 | $9.85 |
| 52 Week High | $24.12 | $17.15 |
Technical Indicators
Market Signals| Indicator | CZNC | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 31.91 | 47.10 |
| Support Level | $19.82 | $11.40 |
| Resistance Level | $22.48 | $13.27 |
| Average True Range (ATR) | 0.52 | 0.65 |
| MACD | -0.23 | -0.10 |
| Stochastic Oscillator | 4.71 | 32.31 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.